Table 1.
Demographic data for DMF-treated patient cohort and for lymphopenic patients.
| Cohort | Grade 2 | Grade 3 | Grade 2 + 3 | |
|---|---|---|---|---|
| N | 221 | 26 | 13 | 39 |
| Age n (%) | ||||
| <40 | 74 (33) | 7 (27) | 0 | 7 (18) |
| 40–55 | 99 (45) | 13 (50) | 6 (46) | 19 (49) |
| >55 | 48 (22) | 6 (23) | 7 (54) | 13 (33) |
| Sex n (%) | ||||
| Male | 59 (27) | 8 (31) | 5 (39) | 13 (33) |
| Female | 162 (73) | 18 (69) | 8 (61) | 26 (67) |
| Race n (%) | ||||
| White | 185 (84) | 25 (96) | 13 (100) | 38 (97) |
| Black | 35 (16) | 1 (4) | 0 | 1 (3) |
| Other | 1 (<1) | 0 | 0 | 0 |
| Most recent DMT n (%) | ||||
| Interferons | 79 (36) | 9 (35) | 2 (15) | 11 (28) |
| Glatiramer acetate | 41 (19) | 3 (12) | 4 (31) | 7 (18) |
| Fingolimod | 9 (4) | 2 (8) | 0 | 2 (5) |
| Teriflunomide | 8 (4) | 0 | 0 | 0 |
| Natalizumab | 23 (10) | 5 (19) | 5 (39) | 10 (26) |
| None | 56 (23) | 6 (23) | 2 (15) | 8 (21) |
| Other | 5 (2) | 1 (4) | 0 | 1 (3) |
| Prior DMTs n (%) | ||||
| 0 | 31 (14) | 3 (12) | 1 (8) | 4 (10) |
| 1–2 | 130 (59) | 17 (65) | 6 (46) | 23 (59) |
| >2 | 60 (27) | 6 (23) | 6 (46) | 12 (31) |
| Time on DMF (months) | ||||
| Median (range) | 11 (1–23) | 14 (4–22) | 19 (9–23) | 15 (4–23) |
DMF: dimethyl fumarate; DMT: disease-modifying therapy.